Study of DNA Samples From Patients With Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at DNA samples from patients with multiple myeloma.

Detailed Description
-----------------
OBJECTIVES: Determine whether there is an increased frequency of 1 or more polymorphic alleles that are associated with clinical endpoints using custom myeloma single nucleotide polymorphism (SNP) chip analysis of banked DNA samples from patients with multiple myeloma. Determine SNPs associated with toxicities caused, not by variations in tumor cell genetics, but by individual genetic variations affecting drug activation, distribution, metabolism, and export (ADME). Determine SNPs associated with response, influenced by the same ADME. Determine SNPs associated with bone disease (as a variable) among patients with multiple myeloma. Determine SNPs associated with epidemiology (i.e., risk factors for the development of multiple myeloma). OUTLINE: This is a retrospective, multicenter study. Banked DNA samples are analyzed using a custom single nucleotide polymorphism (SNP) chip to assess approximately 3,590 SNPs from 1,061 genes that are associated with myeloma growth and response. PROJECTED ACCRUAL: A total of 600 patients will be accrued for this study.

Official Title
-----------------
Proposal for Combining ECOG Myeloma Trial SNP Data

Conditions
-----------------
Multiple Myeloma and Plasma Cell Neoplasm

Intervention / Treatment
-----------------
* Genetic: polymorphism analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of multiple myeloma DNA samples banked from other ECOG studies (and other clinical trial groups [e.g., SWOG and MRC]) PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: polymorphism analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increased frequency of ≥1 polymorphic alleles associated with clinical endpoints using custom myeloma SNP chip analysis of banked DNA samples from patients with multiple myeloma |  | 1 month | 
| SNPs associated with toxicities caused by individual genetic variations affecting drug activation, distribution, metabolism, and export (ADME) |  | 1 month | 
| SNPs associated with response |  | 1 month | 
| SNPs associated with bone disease |  | 1 month | 
| SNPs associated with epidemiology (i.e., risk factors for the development of multiple myeloma) |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma, refractory multiple myeloma